MVT-5873 Drug Asset Due Diligence Report 2026

This MVT-5873 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether MVT-5873 can convert its Monoclonal antibody profile and CA19.9 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	MVT-5873 (query alias: MVT-5873)
Modality / target	Monoclonal antibody; CA19.9; CA19.9 inhibitors
Highest global status	Phase 2
Originator	MabVax Therapeutics, Inc.
Active developers	Sarah Cannon Research Institute LLC, Memorial Sloan Kettering Cancer Center, MabVax Therapeutics, Inc.

The MCP disease footprint includes Pancreatic Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06069778	Phase 1/2	Terminated	1	Primary endpoint not disclosed in English source
NCT04883775	Phase 1	Completed	4	Primary endpoint not disclosed in English source
NCT03801915	Phase 2	Completed	10	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase I/Randomized Phase II, Open-label Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of mFOLFIRINOX With or Without BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

Phase 1/2; n=1; evaluation: Not stated in English source. Reported fields: Phase 1 - The Number and Percentage of Participants With at Least One Dose of Investigational Medicinal Product (IMP) Reporting Treatment Emergent Adverse Events (TEAEs) = 1 Pts

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Phase 2; n=10; evaluation: Not stated in English source. Reported fields: Number of Participants With Disease Recurrence At 1 Year = 2 Pts ; Number of Participants With Disease Recurrence At 1 Year = 0 Pts

HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies.

Phase 1; n=9; evaluation: Positive. Reported fields: AE = GI toxicity (abdominal pain/cramps/diarrhea/nausea) and G1-2 infusion reactions ; AE = GI toxicity (abdominal pain/cramps/diarrhea/nausea) and G1-2 infusion reactions

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

MVT-5873 addresses Pancreatic Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
Not disclosed	BioNTech purchases MabVax Therapeutics' MVT-5873 and additional preclinical antibody assets.	Phase 1	US$5.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination therapy with Anti-ca19-9 antibody and folfiriox in the treatment of”. The milestone feed surfaced a patent-application signal described as “Compositions for therapeutics, targeted pet imaging and methods of their use”. The milestone feed surfaced a patent-application signal described as “NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS a”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO